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A B S T R A C T
Background: The Institute of Medicine emphasizes care timeliness as an important quality metric. We assessed
treatment timeliness in stage I-IIIA lung cancer patients deemed eligible for curative intent therapy and analyzed
the relationship between time to treatment (TTT) and timely treatment (TT) with survival.
Methods: We retrospectively reviewed consecutive cases of stage I-IIIA lung cancer deemed eligible for curative
intent therapy at the VA San Diego Healthcare System between 10/2010–4/2017. We deﬁned TTT as days from
chest tumor board to treatment initiation and TT using guideline recommendations. We used multivariable
(MVA) Cox proportional hazards regressions for survival analyses.
Results: In 177 veterans, the median TTT was 35 days (29 days for chemoradiation, 36 for surgical resection, 42
for deﬁnitive radiation). TT occurred in 33% or 77% of patients when the most or least timely guideline re-
commendation was used, respectively. Patient characteristics associated with longer TTT included other cancer
history, high simpliﬁed comorbidity score, stage I disease, and deﬁnitive radiation treatment. In MVA, TTT and
TT [HR 0.53 (95% CI 0.27, 1.01) for least timely deﬁnition] were not associated with OS in stage I-IIIA patients,
or disease-free survival in subgroup analyses of 122 stage I patients [HR 1.49 (0.62, 3.59) for least timely
deﬁnition].
Conclusion: Treatment was timely in 33–77% of veterans with lung cancer deemed eligible for curative intent
therapy. TTT and TT were not associated with survival. The time interval between diagnosis and treatment may
oﬀer an opportunity to deliver or improve other cancer care.
1. Introduction
The goals for lung cancer therapy are to achieve a cure where
possible and/or palliate and reduce symptom burden and improve
quality of life, depending on the stage and patients' ﬁtness to tolerate
therapy [1,2]. The theoretical harms of treatment delay in patients with
early stage lung cancer include a potential for disease progression to
more advanced stage where curative treatment is no longer possible; in
those with advanced stage and high symptom burden, delays in treat-
ment could unnecessarily lead to prolonged suﬀering [3]. As such, the
Institute of Medicine (IOM) emphasizes timeliness of care as an im-
portant health care quality metric, with the goal to reduce waits and
sometimes harmful delays for both those who receive and those who
give care [4]. Clinical opinion-based guidelines by the American Col-
lege of Chest Physicians (ACCP) [5], British Thoracic Society (BTS) [6],
and the RAND Corporation [7] are available to emphasize and facilitate
timely lung cancer care: the ACCP recommends that surgery should
occur within 4–8 weeks of referral and radiation within 4 weeks where
complex treatment planning is needed [5]; the BTS recommends delays
of no more than 8 weeks for surgery, 7 weeks for radiotherapy, and 4
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T
weeks for chemotherapy [6]; and the RAND Corporation within 6
weeks of the diagnosis date [7].
The impact of treatment timeliness on clinical outcomes is unclear
based on available evidence [3]. To examine the relationship between
time to treatment (TTT) and survival in lung cancer, several factors
should be considered, including the target population (stage of disease
and comorbidities), intent of treatment delivered (curative or pallia-
tive), and precise deﬁnitions of start time and outcomes. TTT is longer
in patients with early stage disease [8] (partly due to the lack of
symptoms) and therefore can be associated with better prognosis. In
addition, timely treatment (TT) for advanced stage lung cancer has a
lower probability of prolonging overall survival (OS); a more appro-
priate target population is those with early stage lung cancer who can
be cured with treatment. The TTT should start at the time of diagnosis
and complete staging since any delay that leads to disease progression/
upstaging will not be recognized until appropriate clinical staging is
performed, and survival time calculated from that point forward.
Up to 50% of patients with non-small cell lung cancer (NSCLC) are
diagnosed with stage I-IIIA disease [9], the treatment of which is ty-
pically aimed at achieving a cure through a combination of lung cancer
resection surgery, deﬁnitive radiation, or combined chemoradiation in
eligible patients. In this project, we aim to more carefully examine the
relationship between the diagnosis to treatment interval and survival in
lung cancer, considering the factors as laid out above. We hypothesize
that in patients with stage I-IIIA lung cancer eligible for curative intent
therapy, TTT, including treatment delay as deﬁned by clinical guide-
lines, is associated with worse OS. We also hypothesize that in a sub-
group of patients with stage I lung cancer undergoing curative intent
treatment, treatment delay is associated with worse disease-free sur-
vival (DFS) following treatment.
2. Methods
2.1. Clinical setting
The VA San Diego Healthcare System (VASDHS) Pulmonary Section
evaluates most of the cases of suspected lung cancer in a diagnostic
clinic. All cases are presented in a weekly multidisciplinary chest tumor
board (CTB) consisting of medical and radiation oncologists, nurse-co-
ordinators, pathologists, pulmonologists, radiologists, and thoracic sur-
geons to establish the diagnosis, stage, and treatment plans. Thereafter, a
board-certiﬁed physician/pulmonologist who presented the patient to
the CTB enters a note in the format of a history and physical examination
in the medical record system and refers patients accordingly. Treatment
by medical oncologists and thoracic surgeons is delivered within the
VASDHS, and by radiation oncologists through outside referral. Patients
treated with surgical resection or deﬁnitive radiation are typically fol-
lowed by the VASDHS Pulmonary Section for surveillance; those with
signs concerning for disease progression/recurrence are routinely re-
presented to the CTB for additional treatment recommendations. To
ensure quality and timely care, the Section keeps an ongoing list of cases
of suspected lung cancer since October 2010. In addition, the VA
healthcare system has an integrated medical record system and keeps
accurate vital records for its patients. All these factors facilitated the
reliability and completeness of the data used for this study.
2.2. Study design & patient selection
The VASDHS Institutional Review Board approved this study
(Protocol #H170091). We retrospectively reviewed consecutive cases
of lung cancer diagnosed and managed from 10/2010 to 4/2017 and
included stage I-IIIA lung cancer patients deemed eligible by the CTB
for curative intent therapy (i.e. lung cancer resection surgery, deﬁnitive
radiation, or concurrent chemoradiation). We deﬁned TTT (primary
predictor) as time from CTB to initiation of treatment, and OS as the
primary outcome. We also assessed DFS in a pre-speciﬁed subgroup
analysis of stage I patients. We used the ACCP's deﬁnition for disease
recurrence/progression following treatment: having the same histology
and systemic metastasis, same histology in diﬀerent lobes and presence
of N2/N3 involvement, or disease recurrence (including locoregional
recurrence) as determined by the CTB after< 2-year intervals [10].
2.3. Confounders
We collected baseline clinical characteristics from CTB notes and
included variables previously known to be associated with survival in
lung cancer: age, sex, race/ethnicity, smoking status/tobacco exposure,
performance status, history of lung cancer in parents or siblings, co-
morbidities, tumor size, clinical stage, histology, and treatment type.
We used the simpliﬁed comorbidity score (SCS) to incorporate the ef-
fect of comorbidities and their respective weights on survival: tobacco
consumption (7 points), diabetes mellitus (5), renal insuﬃciency (4),
respiratory comorbidity (1), cardiovascular comorbidity (1), neoplastic
comorbidity (1), and alcoholism (1); a SCS > 9 has been reported to be
associated with worse survival in patients with stage I-IV NSCLC [11].
We also included lung function [forced expiratory volume in 1 s (FEV1),
diﬀusion capacity of the lung for carbon monoxide (DLCO), and total
lung capacity (TLC)] where available.
2.4. Statistical analyses
We summarized continuous variables as means and standard de-
viations or medians and ranges, and for categorical variables counts and
percentages, and deﬁned clinical stage using the 7th edition of the
American Joint Committee on Cancer TNM staging system. We re-
corded and analyzed TTT as a continuous (days) and categorical (timely
or not) variable. We deﬁned TT using combined (ACCP, BTS, RAND
Corporation) guideline recommendations [5–7]: most timely – for all
treatment modalities, within 4 weeks (28 days) of CTB, and least timely
– for surgical resection, within 8 weeks (56 days); radiation therapy – 7
weeks (49 days), or chemoradiation, within 6 weeks (42 days) of CTB.
We used the Kaplan-Meier method to estimate OS and DFS, log-rank
test to compare the survival distributions between groups, and uni-
variable (UVA) and multivariable (MVA) Cox proportional hazards re-
gressions to examine the relationship between TTT or TT and survival.
We used stepwise backward selection using a p-value cutoﬀ<0.15 for
all clinical variables associated with survival in UVAs for MVAs, HR's
and 95% conﬁdence intervals (CI's) to summarize the eﬀect size, and
deﬁned statistical signiﬁcance as p < 0.05 in two-tailed tests. We
forced our predictors (TTT and TT) into the MVA models regardless of
statistical signiﬁcance and corrected for multiple pairwise comparisons
for treatment type where applicable by multiplying the resulting p-
values by the number of comparisons. All data were managed using
Fig. 1. Flow diagram of included patients.
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REDCap electronic data capture tools hosted at the VA Information
Resource Center [12]; and analyzed using IBM® SPSS® Statistics soft-
ware version 24.0.
3. Results
3.1. Characteristics of Included Patients, primary predictor, and outcome
We included 177 stage I-IIIA patients eligible for curative intent
therapy (Fig. 1); baseline characteristics are as in Table 1. The median
TTT was 35 days for all treatment modalities (29 days for chemor-
adiation, 36 for surgical resection, and 42 for deﬁnitive radiation).
Depending on the deﬁnition of timeliness used, TT occurred in 33%
(using the most timely) or 77% (least timely deﬁnition) of patients
(Table 1). Patient characteristics associated with longer TTT included
other cancer history, high SCS, stage I disease, and deﬁnitive radiation
treatment (Table 2). The median follow-up time was 25 months (in-
terquartile range, IQR 12–40); death occurred in 75 patients (42%). The
median overall survival time (and 95% CI's) was 42 months (25–59);
and 54 months (36–73) for stage I disease, 31 (20–42) stage II, and 25
(20–29) stage IIIA (p= 0.04 by Log-rank pooled over strata).
3.2. Univariable and multivariable cox regressions
In UVA, tobacco exposure (pack years), SCS (points), DLCO % pre-
dicted, tumor size/stage I disease, and treatment modality were asso-
ciated with OS (Table 3). TTT and TT [either most or least timely
(Fig. 2A)] were not associated with better OS. In MVA, higher DLCO %
predicted and treatment category were associated with OS; TTT was not
associated with OS (HR 1.00 for each day, 95% CI 0.99, 1.01) (Table 4A
– Model 1). When categorized as most or least TT, there was a para-
doxical trend towards better OS in patients with delayed treatment as
deﬁned by the least timely deﬁnition (HR 0.53, 95% CI 0.27–1.01)
(Table 4A – Model 2).
Table 1
Patient characteristics.
Patient Characteristic (N=177) Value
Age, years, mean (SD) 68.7 (8.2)
Male sex, n (%) 169 (96)
Race, n (%)
Black/African American 15 (9)
White 142 (80)
Other/declined 20 (11)
Symptom at presentation, n (%)
Chest pain/cough/dyspnea 58 (33)
Hemoptysis 8 (5)
Other 5 (3)
None 106 (60)
ECOG PSa < 2, n (%) 144 (81)
Family history of lung cancer, n (%) 21 (12)
Smoking status, n (%)
Current 100 (57)
Former 70 (40)
Never 7 (4)
Pack yearsa, mean (SD) 50.3 (26.6)
Respiratory comorbidities, n (%)
COPD/asthma 123 (69)
Any respiratory comorbidityc 134 (76)
Cardiovascular comorbidities, n (%)
CAD 54 (31)
Arrhythmia 23 (13)
HF 19 (11)
Any cardiovascular comorbidityc 136 (77)
Other cancer, n (%) 56 (32)
Alcohol dependence, n (%) 21 (12)
DM, n (%) 36 (20)
CKD, n (%) 17 (10)
SCS, mean (SD) 10.1 (3.1)
SCS > 9, n (%) 77 (44)
Psychiatric illness, n (%)
Anxiety/Depression/PTSD 49 (28)
Bipolar/Schizophrenia 8 (5)
Any psychiatric illness 57 (32)
Pulmonary function, mean (SD)
FEV1/FVCa, % 60.5 (14.8)
FEV1, % predicteda 71.5 (23.0)
TLC, % predicteda 107.3 (18.6)
DLCO, % predicteda 75.4 (22.0)
Ventilatory defectsb, n (%)
Obstructive 113 (64)
Restrictive 9 (5)
DLCO limitation 91 (51)
Lesion sizea, cm, mean (SD) 2.8 (1.8)
Histology, n (%)
Adenocarcinoma 78 (44)
Squamous cell carcinoma 42 (24)
Small cell carcinoma 10 (6)
Other or NSCLC, NOS 17 (10)
Presumed 30 (17)
Clinical stage, n (%)
IA 90 (51)
IB 32 (18)
IIA 13 (7)
IIB 11 (6)
IIIA 31 (18)
Primary treatment, n (%)
Surgical resection 59 (33)
SBRTd 64 (36)
XRTd 14 (8)
Chemoradiation 40 (23)
Time to treatment
All modalities
TTT, days, median (IQR) 35 (24–55)
Most TT, n (%) 59 (33)
Least TT, n (%) 136 (77)
Surgical resection
TTT, days, median (IQR) 36 (17–51)
Most TT, n (%) 24 (41)
Least TT, n (%) 46 (78)
SBRT/XRT
TTT, days, median (IQR) 42 (29–67)
Table 1 (continued)
Patient Characteristic (N=177) Value
Most TT, n (%) 17 (22)
Least TT, n (%) 54 (69)
Chemoradiation
TTT, days, median (IQR) 29 (21–36)
Most TT, n (%) 18 (45)
Least TT, n (%) 36 (90)
CAD= coronary artery disease; CKD= chronic kidney disease;
COPD= chronic obstructive pulmonary disease; DLCO= diﬀusion capa-
city of the lung for carbon monoxide; DM=diabetes mellitus; ECOG
PS=Eastern Cooperative Oncology Group Performance Status;
FEV1= forced expiratory volume in 1 s; FVC= forced vital capacity;
HF=heart failure; IQR= interquartile range; NOS=not otherwise spe-
ciﬁed; NSCLC=non-small cell lung cancer; PTSD=post-traumatic stress
disorder; SBRT= stereotactic body radiotherapy; SCS= simpliﬁed co-
morbidity score; SD= standard deviation; TT= timely treatment;
TTT= time to treatment; TLC= total lung capacity; XRT= radiotherapy.
a Missing value (n): ECOG PS (1), Pack years (2), FEV1/FVC (5), FEV1%
predicted (5), TLC % predicted (57), DLCO % predicted (17), Lesion size
(1).
b Deﬁned as FEV1/FVC<0.7 for obstructive ventilatory defect, TLC %
predicted< 80 for restrictive, and DLCO % predicted< 80 for DLCO lim-
itation; missing values were assumed to be normal.
c As deﬁned by the SCS: for respiratory comorbidity, history of tu-
berculosis, pleural eﬀusion or pneumonia, asthma, pulmonary embolism,
chronic hypoxemia, and/or COPD (any); for cardiovascular comorbidity:
congestive HF, CAD, severe valvular disease, arrhythmia requiring treat-
ment, cerebrovascular disease, hypertension, and/or peripheral vascular
disease (any).
d Grouped and analyzed as deﬁnitive radiation (SBRT/XRT).
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3.3. Pre-speciﬁed subgroup analyses of stage I patients
In subgroup analyses of 122 stage I patients, 52 (43%) underwent
surgical resection and 9 (7%) adjuvant therapy. The median TTT for the
entire stage I subgroup was 37 days (36 days for surgical resection and
41 days for deﬁnitive radiation). TT occurred in 30–74% of patients,
depending on the deﬁnition of timeliness used. The median follow-up
time was 26 months (IQR 13–40), with 35 patients (29%) having dis-
ease recurrence/progression and 44 (36%) deaths. The median DFS
time was not reached (> 26 months); the mean DFS time was 42
months (Fig. 2B). UVA and MVA results for DFS are shown in Tables 3
and 4B, respectively. TTT (Table 4B – Model 1) and TT [either most or
least timely (Table 4B – Model 2)] were not associated with DFS.
4. Discussion
In consecutive lung cancer patients with stage I-IIIA disease eligible
for curative intent therapy at the VASDHS from 2010 to 2017, TTT and
TT were not associated with better OS, or DFS in stage I patients. To the
best of our knowledge, our study is the ﬁrst to examine the relationship
between TTT/TT and DFS in lung cancer.
Previous studies have examined the relationship between TTT and
OS in lung cancer. For instance, Gould and coworkers [13] analyzed
129 consecutive patients with NSCLC (29% stage I-II and 33% stage III
disease) diagnosed at the VA Palo Alto Healthcare System from 2002 to
2003 (median diagnosis-to-treatment time 22 days) and found that OS
was paradoxically worse in patients treated within 84 days compared
to> 84 days after initial suspicion (HR 1.6, 95% CI 1.3–1.9) [13].
Olsson and coworkers [14] systematically reviewed published studies
from 1995 to 2007 and found that in 15 studies with multivariable
survival analyses, eight reported no association between timely care
and OS, four reported an association between delayed care and better
OS, and three an association between timely care and better OS.
However, the deﬁnition of timely care varied greatly, including in the
three studies that showed associations between timely care and better
OS. In one study [15], delayed care was deﬁned as time from initial
tumors missed on screening but identiﬁed one year later (hence at least
a one-year delay to treatment), and in the other two [16,17], the time
interval most accurately reﬂected time-to-diagnosis, and not TTT.
Table 2
Associations of patient characteristics and time to treatment.
Patient Characteristic (N=177) Mean Diﬀerence,a days (95% CI)
Age (> 70/≤70) −10.2 (−25.3, 4.99)
Sex (F/M) −3.06 (−32.5, 26.43)
Race (Nonwhite/White) 20.9 (−3.50, 45.2)
Symptomatic (N/Y) −2.66 (−15.2, 9.83)
ECOG (≥2/< 2) −5.46 (−21.2, 10.2)
Family history (N/Y) 6.06 (−12.9, 25.0)
Pack years (> 30/≤30) −4.45 (−18.9, 10.0)
DM (N/Y) 5.01 (−10.2, 20.2)
CKD (N/Y) 2.80 (−18.0, 23.6)
COPD (N/Y) −3.25 (−16.5, 9.98)
Any respiratory comorbidity (N/Y) −9.24 (−23.5, 4.98)
CAD (N/Y) 6.69 (−23.7, 2.76)
Any CVD comorbidity (N/Y) 3.94 (−10.6, 18.4)
Other cancer history (N/Y) −17.4 (-34.4, -0.47)
Alcohol dependence (N/Y) −25.8 (−66.2, 14.6)
SCS > 9 (N/Y) −13.6 (-26.9, -0.25)
Any psychiatric illness (N/Y) 8.43 (−1.97, 18.8)
Ventilatory defect (N/Y)
Obstructive −4.06 (−16.8, 8.68)
Restrictive 4.29 (−23.6, 32.2)
DLCO limitation −0.53 (−12.8, 11.7)
Tumor size < 2 cm −3.34 (−16.0, 9.30)
SCLC (N/Y) 13.2 (6.45, 58.6)
Stage I (N/Y) −13.7 (-26.8, -0.62)
Treatment categoryb
Surgery vs. SBRT/XRT −17.8 (-34.7, -0.86)
Surgery vs. chemoradiation 8.95 (−1.93, 19.8)
SBRT/XRT vs. Chemoradiation 26.7 (10.4, 43.1)
CAD= coronary artery disease; CI= conﬁdence interval; CKD= chronic
kidney disease; COPD= chronic obstructive pulmonary disease; CTB= chest
tumor board; CVD= cardiovascular disease; DLCO= diﬀusion capacity of the
lung for carbon monoxide; DM=diabetes mellitus; ECOG PS=Eastern
Cooperative Oncology Group Performance Status; FEV1= forced expiratory
volume in 1 s; SBRT= stereotactic body radiotherapy; SCLC= small cell lung
cancer; SCS= simpliﬁed comorbidity score; TLC= total lung capacity;
XRT= radiotherapy.
Bolded variables: statistically signiﬁcant, p < 0.05.
a Independent-samples tests (t-test for equality of means and Levene's test for
equality of variances).
b Independent-samples Kruskal-Wallis test for nonparametric distribution,
p < 0.001.
Table 3
Univariable cox regression analyses of survival.
Variable HR (95% CI)
OS (Stage I-IIIA) DFS (Stage I)
Age, per year 1.02 (0.99, 1.04) 1.02 (0.98, 1.06)
Sex (F/M) 0.42 (0.10, 1.72) 1.16 (0.28, 4.86)
Race (Nonwhite/White) 1.09 (0.63, 1.88) 1.17 (0.45, 3.03)
Symptomatic (N/Y) 0.88 (0.56, 1.40) 1.67 (0.76, 3.67)
ECOG PS (≥2/< 2) 1.21 (0.70, 2.11) 1.68 (0.81, 3.50)
Family history (N/Y) 1.29 (0.62, 2.69) 0.21 (0.03, 1.51)
Each pack year 1.01 (1.00, 1.02) 1.02 (1.01, 1.03)
DM (N/Y) 0.94 (0.54, 1.66) 1.47 (0.60, 3.49)
CKD (N/Y) 0.50 (0.25, 1.01) 0.63 (0.22, 1.80)
COPD (N/Y) 0.74 (0.44, 1.22) 0.65 (0.29, 1.43)
Any respiratory comorbidity (N/Y) 0.65 (0.37, 1.14) 0.40 (0.14, 1.13)
CAD (N/Y) 0.99 (0.60, 1.64) 2.5 (1.05, 6.12)
HF (N/Y) 0.70 (0.36, 1.37) 1.62 (0.50, 5.28)
Any CVD comorbidity (N/Y) 0.89 (0.51, 1.54) 1.46 (0.64, 3.35)
Other cancer history (N/Y) 0.82 (0.51, 1.33) 0.74 (0.37, 1.47)
Alcohol dependence (N/Y) 0.76 (0.40, 1.44) 0.77 (0.30, 1.99)
Comorbidity score
SCS, per point 1.08 (1.01, 1.15) 1.03 (0.93, 1.14)
SCS > 9 (N/Y) 0.64 (0.40, 1.00) 0.88 (0.45, 1.70)
Any psychiatric illness (N/Y) 0.79 (0.49, 1.28) 0.86 (0.43, 1.71)
Pulmonary function (per % pred)
FEV1 0.99 (0.98, 1.00) 0.99 (0.98, 1.01)
TLC 1.00 (0.98, 1.01) 1.01 (0.99, 1.04)
DLCO 0.99 (0.97, 1.00) 0.98 (0.97, 1.00)
Ventilatory defect (N/Y)
Obstructive 0.85 (0.53, 1.36) 0.71 (0.34, 1.49)
Restrictive 0.92 (0.37, 2.28) 1.30 (0.18, 9.54)
DLCO limitation 0.67 (0.42, 1.07) 0.54 (0.27, 1.07)
Tumor size, per cm 1.21 (1.09, 1.34) 1.41 (1.05, 1.89)
SCLC (N/Y) 0.87 (0.35, 2.16) 0.50 (0.12, 2.11)
Clinical stagea 1.82 (1.15, 2.88) 0.43 (0.22, 0.85)
Treatment category
Surgical resection 0.32 (0.17, 0.59) ref
SBRT/XRT 0.57 (0.34, 0.97) 2.07 (1.02, 4.24)
Chemoradiation ref N/A
Time to treatment
TTT, per day 1.00 (0.99, 1.00) 1.00 (0.99, 1.01)
Most TT (N/Y) 0.95 (0.60, 1.52) 1.11 (0.54, 2.26)
Least TT (N/Y) 0.54 (0.29, 1.01) 0.86 (0.39, 1.90)
CAD= coronary artery disease; CI= conﬁdence interval; CKD= chronic
kidney disease; COPD= chronic obstructive pulmonary disease; CTB= chest
tumor board; CVD= cardiovascular disease; DFS= disease-free survival;
DLCO= diﬀusion capacity of the lung for carbon monoxide; DM=diabetes
mellitus; ECOG PS=Eastern Cooperative Oncology Group Performance Status;
F= female; FEV1= forced expiratory volume in 1 s; HF=heart failure;
HR=hazard ratio; M=male; OS= overall survival; SBRT= stereotactic body
radiotherapy; SCLC= small cell lung cancer; SCS= simpliﬁed comorbidity
score; TLC= total lung capacity; TT= timely treatment; TTT= time to treat-
ment; XRT= radiotherapy.
Bolded variables: statistically signiﬁcant, p < 0.05.
a Categorized as stage I (N/Y) for stage I-IIIA patients, or stage IA/IB for
stage I patients.
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Fig. 2. A: Kaplan-Meier Estimates∗ of
Overall Survival in Stage I-IIIA Patients.
Legend: Kaplan-Meier estimates of OS in i)
all stage I-IIIA lung cancer eligible for
curative intent therapy, stratiﬁed by ii)
clinical stage, iii) simpliﬁed comorbidity
score, and iv) least TT. ∗P-values from
Log-rank tests, pooled over strata.
CI=conﬁdence interval; mo's=months;
MST=median survival time; OS=overall
survival; SCS=simpliﬁed comorbidity
score; TT= timely treatment. B: Kaplan-
Meier Estimates∗† of Disease-free Survival
in Stage I Patients. Legend: Kaplan-Meier
estimates of DFS in i) all stage I lung cancer
eligible for curative intent therapy,
stratiﬁed by ii) clinical stage, iii) treatment
type, and iv) least TT. *P-values from Log-
rank tests, pooled over strata. †Median
survival time not reached in all
groups (>26 months). CI = conﬁdence
interval; DFS = disease-free survival;
mo's = months; SBRT = stereotactic body
radiotherapy; TT = timely treatment.
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Recently, Nadpara and coworkers [18] analyzed 16,747 elderly lung
cancer patients included in the Surveillance, Epidemiology, and End
Results (SEER) database from 2002 to 2007 (median diagnosis to
NSCLC treatment time 27 days), and found that delayed care was again
paradoxically associated with better survival (HR 0.68, 95% CI
0.66–0.71) in MVA. When stratiﬁed by lung cancer stage, there was a
trend towards better survival in stage I/II patients receiving timely care,
however the results were not statistically signiﬁcant. Notably, the
author excluded patients with a prior history of malignancy (11,846
patients, 15% of the patients screened). In a similar study, Gomez and
coworkers [19] analyzed SEER data on 28,732 patients with histolo-
gically conﬁrmed NSCLC from 2004 to 2007 (median diagnosis-to-
treatment time 27 days), and found that in MVA, TT was associated
with better survival (HR 0.86, 95% 0.80–0.91) in patients with loca-
lized disease. In those with regional disease, there was a trend towards
worse survival with TT (HR 1.05, 95% CI 0.99–1.11), and in distant
disease TT was again paradoxically associated with worse survival (HR
1.35, 95% CI 1.28–1.42) [19]. Most recently, Yang and coworkers [20]
analyzed 4984 patients with stage IA squamous cell carcinoma included
in the National Cancer Database from 2006 to 2011 (median diagnosis-
to-treatment time 38 days) and found that in MVA, there was a 13%
increased hazard of overall death in those who had surgery 38 days or
later after diagnosis (HR 95% CI 1.02–1.25, p=0.02). Notably, there
was no signiﬁcant diﬀerence in the pathologic tumor or nodal stage
between timely and delayed lobectomy [20].
Compared to our study, a few notable diﬀerences exist for inter-
pretation. Studies by Nadpara [18] and Gomez [19] and coworkers
excluded patients with other cancers (32% of patients in our study), and
Gomez [19] and Yang [20] and coworkers excluded patients with
presumed lung cancer who tend to have high comorbidity burden and
poor prognosis (17% in our study). Since TTT tends to be longer in
patients with a high comorbidity burden [14], excluding sicker patients
increases the chance of false-positive ﬁndings. In addition, none of the
studies included tobacco exposure and lung function (notably DLCO %
predicted [21,22]) as covariates which are important prognostic vari-
ables in lung cancer. Last, lung cancer-speciﬁc survival including DFS, a
more logical outcome to investigate the signiﬁcance of timeliness of
lung cancer treatment, was not assessed in any of these studies.
Another logical outcome is tumor upstaging associated with treat-
ment delay. To this end, Liberman and coworkers [23] analyzed 256
patients who underwent lung cancer resection surgery (89% with pa-
thologic stage I-IIIA) at the Montreal General Hospital between 1993
and 2002 (median surgical visit to operation time 82 days), and found
that preoperative delay was not associated with surgical stage cate-
gories. Clinical stage was not available in this study to assess the pro-
portions of patients upstaged at the time of surgery. Similarly, Maiga
and coworkers [24] analyzed 197 lung cancer patients who had a tissue
diagnosis and subsequently underwent surgical resection (median di-
agnosis to surgery time 53 days) at the VA Tennessee Valley Healthcare
System from 2005 to 2015, and in univariable analyses, found no sig-
niﬁcant correlation between time to resection with tumor progression,
deﬁned as tumor growth > 0mm between radiographic and patho-
logic tumor size; this deﬁnition is unlikely to be sensitive to small/
subtle changes in tumor growth. In our subgroup analysis of stage I
patients, 52 (43%) underwent surgical resection, 18 of whom (35%)
were upstaged at the time of surgery; there was no diﬀerence in TTT in
those upstaged versus those not upstaged (mean 42 vs. 33 days, re-
spectively, t-test for equality of means p=0.25).
Partly due to the observational nature of available studies, our un-
derstanding of the impact of delayed care on lung cancer outcomes is
incomplete. However, one can make references to the causal relation-
ship between TTT/TT and survival (biologically caused by disease
progression) with some key considerations: consistency and strength of
association, linearity/dose-response relationship, and plausibility of
alternative explanations. Based on our review, there is an inconsistent
and weak association between TT and survival (HR's are con-
sistently< 2 in patients with delayed care where there are positive
associations); no available study describes a dose-response relationship
between TTT and survival. In addition, there are alternative explana-
tions for positive associations including for the results from the study by
Yang and coworkers [20], in which patients who are healthier and/or
with better lung function may have received lobectomy sooner than
those who are sicker and/or with worse lung function.
While TTT/TT were not associated with improved survival in our
Table 4A
Multivariable cox regression analyses* of overall survival in stage I-IIIA pa-
tients.
Model 1†
Variable HR (95% CI) P-value
DLCO, per 10% predicted 0.86 (0.76, 0.98) 0.02
Treatment category∗∗
Surgery 0.32 (0.16, 0.62) 0.003
SBRT/XRT 0.40 (0.21, 0.76) 0.02
Chemoradiation ref Ref
TTT, per day 1.00 (0.99, 1.01) 0.56
Model 2‡
Variable HR (95% CI) P-value
Each pack year 1.01 (1.00, 1.02) 0.11
DLCO, per 10% predicted 0.86 (0.75, 0.98) 0.02
Treatment category**
Surgery 0.36 (0.18, 0.69) 0.006
SBRT/XRT 0.39 (0.21, 0.73) 0.009
Chemoradiation ref ref
Least TT (N/Y) 0.53 (0.27, 1.01) 0.054
*Stepwise backward selection including baseline characteristics with
p < 0.15: smoking history (pack year), SCS, DLCO % predicted, stage I/II-IIIA
disease, treatment category.
∗∗P-values corrected for 3 pairwise comparisons.
†Overall model P < 0.001; no signiﬁcant interaction between DLCO and
treatment category (p= 0.95).
‡Overall model P < 0.001; no signiﬁcant interaction between DLCO and pack
year (p=0.37) or timely treatment and treatment category (p= 0.73).
Table 4B
Multivariable cox regression analyses* of disease-free survival in stage I pa-
tients.
Model 1†
Variable HR (95% CI) P-value
Each pack year 1.02 (1.00, 1.03) 0.01
CAD (N/Y) 3.25 (1.25, 8.44) 0.02
Stage IA/IB 0.32 (0.15, 0.66) 0.002
Surgical resection (N/Y) 2.26 (1.07, 4.78) 0.03
TTT, per day 1.00 (0.99, 1.01) 0.74
Model 2
Each pack year 1.02 (1.01, 1.03) 0.008
CAD (N/Y) 3.50 (1.35, 9.07) 0.01
Stage IA/IB 0.30 (0.14, 0.63) 0.002
Surgical resection (N/Y) 2.35 (1.11, 4.94) 0.03
Least TT (N/Y) 1.49 (0.62, 3.59) 0.37
CAD= coronary artery disease; CI= conﬁdence interval; DLCO=diﬀusion
capacity of the lung for carbon monoxide; HR=hazard ratio;
SBRT= stereotactic body radiotherapy; SCS= simpliﬁed comorbidity score;
TT= timely treatment; TTT= time to treatment; XRT= radiotherapy.
*Stepwise backward selection including baseline characteristics with
p < 0.15: family history of lung cancer, smoking history (pack year), any
respiratory comorbidity, CAD, DLCO % predicted, stage, surgical resection.
†Overall ﬁnal model P < 0.001; no signiﬁcant interaction between CAD and
pack year (p=0.06) or CAD and surgical treatment (p= 0.22).
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study, one should be careful in not assuming that extending the period
between diagnosis and treatment beyond the limits of timeliness as
deﬁned by practice guidelines will have no impact on survival. Our
ﬁndings should not be interpreted as a “ticket” to extend workups or
delay treatment beyond recommended limits or lessen a diligence to
keep timeliness within these limits as a sensible quality measure. In
addition, eﬀorts to improve timeliness should be made with careful
considerations of modiﬁable/nonmodiﬁable factors. In a systematic
analysis, institutional factors explained only< 1% of the variations in
treatment times [25]. Overcoming patient self-blame and stigma [26]
and facilitating positive coping [27] strategies may play an important
role in improving timeliness. Moreover, the time interval between di-
agnosis and treatment may oﬀer an opportunity to deliver or improve
other quality cancer care. In this cancer continuum, the IOM highlights
needs in patient care planning, psychosocial support, prevention of
treatment related eﬀects, and family caregiver support [28]. Develop-
ment and implementation of health services including cancer re-
habilitation may decrease treatment related morbidity, increase cancer
treatment options, and improve physical and psychological health
outcomes [29].
The prevalence COPD (64% conﬁrmed by lung function testing) was
higher in our study compared to others [30,31] including in veterans
(53–56%) [32], possibly due to higher tobacco and/or environmental/
occupational exposure or referral bias. The prevalence of diabetes
(20%) and other cancer (32%) were somewhat comparable to other
veteran populations (26% and 21%, respectively) [32]. Congestive
heart failure (HF, 11%) was similarly prevalent compared to lung
cancer patients included in the Nebraska Cancer Registry (13%) [30]
and SEER database (12%) [31].
Like previous studies, our study reports the likelihood of receiving
timely care decreasing with high comorbidity burden, NSCLC (com-
pared to SCLC) histology, and early stage disease [14,18,19,33]. Ra-
diation was associated with the longest TTT compared to other treat-
ment modalities, likely due to outside referral. Like existing literature,
tobacco exposure, comorbidity burden, DLCO % predicted, tumor size,
stage, and treatment type were associated with survival in our study.
Unlike previous studies, HF [30] and SCLC histology were not asso-
ciated with survival, likely due to a small sample size. Timely treatment
(least timely deﬁnition) was paradoxically signiﬁcantly/borderline as-
sociated with worse OS, likely due to confounding/residual con-
founding eﬀects of stage and/or comorbidities. Not having a history of
CAD or lung cancer resection surgery as treatment was associated with
worse DFS, possibly due to survivor bias and/or confounding eﬀects of
stage.
Our study is limited by its retrospective, single-institutional nature;
these ﬁndings may not be generalizable due to all patients included
from the VA healthcare system. Also, the deﬁnition of TTT starting at
the time of weekly CTB conferences does not include preceding time
including time of ﬁrst imaging to cancer diagnosis, tissue diagnosis to
appropriate staging, and diagnosis to CTB presentation which may be
delayed and potentially inﬂuence outcomes. In addition, we did not
have information on the reason for treatment delay and lung cancer-
speciﬁc mortality. Last, our sample size may not have adequate power
to detect a signiﬁcant association between TTT and survival. Our study
also has strengths. First, we maximized the accuracy of the data col-
lected by extracting patient characteristics including comorbidities that
were entered into the electronic medical record system by board-cer-
tiﬁed physicians. Second, we included many of the variables previously
known to be associated with survival in lung cancer, including tobacco
exposure and lung function which tend to be missing in large national
databases. Third, the VA healthcare system keeps accurate and up-to-
date vital records of its patients, allowing for accurate OS analyses.
Fourth we assessed DFS, a more logical outcome in a subgroup of stage I
patients.
We conclude that in a single-institutional analysis of stage I-IIIA
lung cancer patients deemed eligible for curative intent therapy,
treatment was timely in 33% or 77% of veterans, depending on the
guideline recommendation used. Treatment delay was not associated
with overall survival in stage I-IIIA, or disease-free survival in stage I
patients.
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